Peptidomimetic Therapeutic Agents Targeting the
... (a) those using an activated water molecule as the nucleophile that attacks the scissile amide bond (e.g., zinc metalloproteases and aspartate proteases) or (b) those using the nucleophilic side chain of an amino acid residue in order to initiate amide bond hydrolysis (e.g., serine or cysteine prote ...
... (a) those using an activated water molecule as the nucleophile that attacks the scissile amide bond (e.g., zinc metalloproteases and aspartate proteases) or (b) those using the nucleophilic side chain of an amino acid residue in order to initiate amide bond hydrolysis (e.g., serine or cysteine prote ...
MEMORANDUM Date: April 9, 2012 To: Vancomycin File From
... states that the new Clinical Studies section explains what is meant by C. difficileassociated diarrhea in the new studies that led to this changed indication, as well as the efficacy endpoint by which resolution of CDAD was measured. (See ViroPharma Dec. 22, 2011 CP Supplement at 7.) CDAD as defin ...
... states that the new Clinical Studies section explains what is meant by C. difficileassociated diarrhea in the new studies that led to this changed indication, as well as the efficacy endpoint by which resolution of CDAD was measured. (See ViroPharma Dec. 22, 2011 CP Supplement at 7.) CDAD as defin ...
BRIDION - Merck.com
... rivaroxaban, and dabigatran up to ~25% and ~50% at Cmax levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively. Since bleeding risk has been studied systematically with only heparin and low molecular weight heparin thromboprophylaxis and 4 mg/kg doses of sugammadex coagulatio ...
... rivaroxaban, and dabigatran up to ~25% and ~50% at Cmax levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively. Since bleeding risk has been studied systematically with only heparin and low molecular weight heparin thromboprophylaxis and 4 mg/kg doses of sugammadex coagulatio ...
DH 250 - Cypress College
... regular use of high dose inhaled corticosteroids in the past 12 months regular use of injected long acting corticosteroids daily use of oral corticosteroids alternate-day oral corticosteroids prolonged use of oral corticosteroids in the past year ...
... regular use of high dose inhaled corticosteroids in the past 12 months regular use of injected long acting corticosteroids daily use of oral corticosteroids alternate-day oral corticosteroids prolonged use of oral corticosteroids in the past year ...
Prescribing Information
... Pregnancy Category C: There are no adequate and well-controlled studies of desloratadine and pseudoephedrine in combination in pregnant women. Neither are there animal reproduction studies conducted with the combination of desloratadine and pseudoephedrine. Desloratadine was not teratogenic in rats ...
... Pregnancy Category C: There are no adequate and well-controlled studies of desloratadine and pseudoephedrine in combination in pregnant women. Neither are there animal reproduction studies conducted with the combination of desloratadine and pseudoephedrine. Desloratadine was not teratogenic in rats ...
Prescribing Information - PI
... antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s ...
... antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s ...
Full Prescribing Information
... infusion for more than a few hours may be associated with an increased risk of thrombophlebitis. To avoid potential interruptions in drug delivery, the patient must have immediate access to a backup infusion pump and infusion sets. The ambulatory infusion pump used to administer Remodulin should: (1 ...
... infusion for more than a few hours may be associated with an increased risk of thrombophlebitis. To avoid potential interruptions in drug delivery, the patient must have immediate access to a backup infusion pump and infusion sets. The ambulatory infusion pump used to administer Remodulin should: (1 ...
Antibiotics
... Bayer studies - 1% incidence of arthralgia (90% had CF). Control groups had similar side effect profile as study group. No radiographic evidence of joint changes in any study. ...
... Bayer studies - 1% incidence of arthralgia (90% had CF). Control groups had similar side effect profile as study group. No radiographic evidence of joint changes in any study. ...
vitekta - Gilead
... antiretroviral therapy. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, ...
... antiretroviral therapy. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, ...
View Full Prescribing Information - AcipHex Sprinkle (rabeprazole
... Published observational studies suggest that PPI therapy like ACIPHEX Sprinkle may be associated with an increased risk of Clostridium difficile associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve [see Adverse Reactions (6. ...
... Published observational studies suggest that PPI therapy like ACIPHEX Sprinkle may be associated with an increased risk of Clostridium difficile associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve [see Adverse Reactions (6. ...
t.5
... mg/day). Even though these low doses are unlikely to result in a therapeutic response, concern for both the cardiovascular and other SE effect in the elderly is sufficient to warrant caution. Most clinicians would carefully evaluate S.U. weekly and if no SE are observed eg. (changes in visual acuity ...
... mg/day). Even though these low doses are unlikely to result in a therapeutic response, concern for both the cardiovascular and other SE effect in the elderly is sufficient to warrant caution. Most clinicians would carefully evaluate S.U. weekly and if no SE are observed eg. (changes in visual acuity ...
HIGHLIGHTS OF PRESCRIBING INFORMATION mg tablet once
... ATACAND can cause symptomatic hypotension. Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Patients with symptomatic hypotension may require tem ...
... ATACAND can cause symptomatic hypotension. Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Patients with symptomatic hypotension may require tem ...
WARFARIN
... derivatives resulted in malformations, including structural defects (13.9%), in utero fetal death (13%), and neonatal hemorrhage (1.8%) (Guillot, 1979). . In another study of 418 pregnancies exposed to warfarin, 2 out of 3 had normal outcomes, 1 of 6 had malformations, and 1 of 6 resulted in abortio ...
... derivatives resulted in malformations, including structural defects (13.9%), in utero fetal death (13%), and neonatal hemorrhage (1.8%) (Guillot, 1979). . In another study of 418 pregnancies exposed to warfarin, 2 out of 3 had normal outcomes, 1 of 6 had malformations, and 1 of 6 resulted in abortio ...
Metabolism and drug interactions of 3-hydroxy-3
... to some extent in plasma. Therefore, variations in carboxyesterase activity might in¯uence the individual response to these statins [18]. Due to their rapid metabolism in gut and liver, the systemic bioavailability is relatively low, but does not correspond with their biological activity, since thei ...
... to some extent in plasma. Therefore, variations in carboxyesterase activity might in¯uence the individual response to these statins [18]. Due to their rapid metabolism in gut and liver, the systemic bioavailability is relatively low, but does not correspond with their biological activity, since thei ...
iPPI small molecule inhibitor of Protein
... iPPI mostly around privileged structures including peptido-mimetic compounds or specific scaffolds[13-22]. Here we will give a global overview of the various profiling that have been carried out on existing iPPI and present a synthetic depiction of the generic physico-chemical profile of these small ...
... iPPI mostly around privileged structures including peptido-mimetic compounds or specific scaffolds[13-22]. Here we will give a global overview of the various profiling that have been carried out on existing iPPI and present a synthetic depiction of the generic physico-chemical profile of these small ...
Intravenous General Anesthesia for Patients with
... level included those who were given an antiepileptic. In patients not given an antiepileptic, there were no differences in the required dose of propofol and emergence among patients with autism, cerebral palsy, and intellectual disability [7]. It reported that propofol dose required for anesthesia a ...
... level included those who were given an antiepileptic. In patients not given an antiepileptic, there were no differences in the required dose of propofol and emergence among patients with autism, cerebral palsy, and intellectual disability [7]. It reported that propofol dose required for anesthesia a ...
Zyrtec®
... experiments in mice have shown that systemically administered cetirizine does not significantly occupy the cerebral H1-receptors. In addition to its anti-H1 effect, cetirizine was shown to display anti-allergic activities: at a dose of 10 mg once or twice daily, it inhibits the late phase recruitmen ...
... experiments in mice have shown that systemically administered cetirizine does not significantly occupy the cerebral H1-receptors. In addition to its anti-H1 effect, cetirizine was shown to display anti-allergic activities: at a dose of 10 mg once or twice daily, it inhibits the late phase recruitmen ...
LETTERS
... COX-2 inhibitors should reduce their activity and also should act synergistically with the antiplatelet activity of COX-1 inhibitors. A clinical trial of a selective COX-2 inhibitor plus aspirin (an irreversible COX-1 inhibitor), compared with aspirin alone, would be of great interest. Furthermore, ...
... COX-2 inhibitors should reduce their activity and also should act synergistically with the antiplatelet activity of COX-1 inhibitors. A clinical trial of a selective COX-2 inhibitor plus aspirin (an irreversible COX-1 inhibitor), compared with aspirin alone, would be of great interest. Furthermore, ...
Memorin - Beximco Pharmaceuticals Ltd.
... Side Effects The rates of discontinuation from controlled clinical trials of Donepezil hydrochloride due to adverse events for the Donepezil hydrochloride 5 mg/day treatment groups were comparable to those of placebo-treatment ...
... Side Effects The rates of discontinuation from controlled clinical trials of Donepezil hydrochloride due to adverse events for the Donepezil hydrochloride 5 mg/day treatment groups were comparable to those of placebo-treatment ...
Administration
... antibiotics. Regular monitoring of serum levels is important to ensure that there is enough present throughout a 24-hour period to act with the -lactam. Because gentamicin may be given for several weeks in this context, it is also important to ensure that the drug is being adequately renally excret ...
... antibiotics. Regular monitoring of serum levels is important to ensure that there is enough present throughout a 24-hour period to act with the -lactam. Because gentamicin may be given for several weeks in this context, it is also important to ensure that the drug is being adequately renally excret ...
Guideline on the Evaluation of the Pharmacokinetics of
... It may not be feasible to conduct the study in patients with the condition for which the drug is indicated. An acceptable alternative is to use volunteers with hepatic disease. It is acknowledged that recruitment of suitable subjects may pose a difficulty. The most common patient categories are subj ...
... It may not be feasible to conduct the study in patients with the condition for which the drug is indicated. An acceptable alternative is to use volunteers with hepatic disease. It is acknowledged that recruitment of suitable subjects may pose a difficulty. The most common patient categories are subj ...
PI/Mobic PI
... history of serious GI events. The consequences of such events are generally more serious in the elderly. Minor upper GI problems, such as dyspepsia, are common and may occur at any time during NSAID therapy. Therefore physicians and patients should remain alert for ulceration and bleeding, even in t ...
... history of serious GI events. The consequences of such events are generally more serious in the elderly. Minor upper GI problems, such as dyspepsia, are common and may occur at any time during NSAID therapy. Therefore physicians and patients should remain alert for ulceration and bleeding, even in t ...
Selective phosphodiesterase inhibitors for the treatment
... inhibitors such as opsonized zymosan-stimulated superoxide generation [70,71], platelet-activating factor (PAF)- and C5a-induced LTC4 production, as well as chemotaxis [25,72]. Furthermore, in the presence of a b-adrenoceptor agonist, PDE4 inhibitors reduced the release of eosinophil cationic protei ...
... inhibitors such as opsonized zymosan-stimulated superoxide generation [70,71], platelet-activating factor (PAF)- and C5a-induced LTC4 production, as well as chemotaxis [25,72]. Furthermore, in the presence of a b-adrenoceptor agonist, PDE4 inhibitors reduced the release of eosinophil cationic protei ...
Discovery and development of direct thrombin inhibitors
Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibitors that have a broader mechanism of action by both inhibiting factor IIa (thrombin) and Xa. A recent review of patents and literature on thrombin inhibitors has demonstrated that the development of allosteric and multi-mechanism inhibitors might lead the way to a more safer anticoagulant.